TLC C 53
Alternative Names: LIP-PGE1; VentusLatest Information Update: 02 Aug 2002
At a glance
- Originator The Liposome Company
- Developer Taisho Pharmaceutical; The Liposome Company
- Class Prostaglandins
- Mechanism of Action Platelet aggregation inhibitors; Prostaglandin E1 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Coronary artery restenosis; Cystic fibrosis; Inflammation; Myocardial infarction; Peripheral vascular disorders; Septic shock; Systemic inflammatory response syndrome; Thrombosis
- Discontinued Adult respiratory distress syndrome
Most Recent Events
- 31 May 2000 The Liposome Company has been acquired by Elan Corporation
- 16 Sep 1998 Discontinued-II for Adult respiratory distress syndrome in European Union (Unknown route)
- 16 Sep 1998 Discontinued-II for Adult respiratory distress syndrome in Japan (Unknown route)